|Bid||1.7000 x 3200|
|Ask||1.7500 x 900|
|Day's Range||1.5148 - 1.7500|
|52 Week Range||0.7000 - 2.9400|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.46|
Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study analyzing data from the historical use of DSUVIA (sufentanil sublingual tablet 30 mcg) for various same-day plastic surgery procedures.
AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) is possibly approaching a major achievement in its business, so we would...